Get the Stockscreener App
56.07
1.26%
0.70
Merus N V stock is traded at $56.07, with a volume of 1.83M.
It is up +1.26% in the last 24 hours and up +24.46% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$55.37
Open:
$54.71
24h Volume:
1.83M
Relative Volume:
1.82
Market Cap:
$3.88B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-14.19
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+1.69%
1M Performance:
+24.46%
6M Performance:
+25.04%
1Y Performance:
-2.15%
1-Day Range:
$53.81
$56.55
1-Week Range:
$49.46
$57.66
52-Week Range:
$33.19
$61.28
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
56.07 | 3.82B | 35.93M | -244.56M | -157.31M | -3.95 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus, N.V. Provides Updates on Clinical Development - marketscreener.com
Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News
Merus Announces Promising Phase 2 Trial Results - TipRanks
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan
Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com
Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts - Defense World
Lazard Asset Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Price Target Raised to $110.00 - Defense World
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT - Yahoo Finance
Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook - Investing.com Australia
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data - MSN
Merus shares rise as Needham lifts price target to $88 By Investing.com - Investing.com South Africa
Merus stock target holds at $88, Truist affirms Buy rating By Investing.com - Investing.com South Africa
Northern Trust Corp Has $3.21 Million Stake in Merus (NASDAQ:MRUS) - Defense World
Merus stock target holds at $88, Truist affirms Buy rating - Investing.com Australia
Merus shares rise as Needham lifts price target to $88 - Investing.com Australia
Merus stock price target raised to $110 at BMO Capital By Investing.com - Investing.com Nigeria
Merus stock price target raised to $110 at BMO Capital - Investing.com
Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeigen robuste Wirksamkeit und Dauerhaftigkeit bei der Erstlinienbehandlung von PD-L1-positivem r/m HNSCC - GlobeNewswire Inc.
Vorläufige Ergebnisse von Merus zu Petosemtamab mit - GlobeNewswire
Merus (NASDAQ:MRUS) Shares Gap Up After Analyst Upgrade - Defense World
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC - Yahoo Finance
Merus’ ASCO data bolster case for first-in-class bispecific - BioCentury
Big Gains For Imunon, Merus, And Douglas Elliman - Finimize
Merus combo trounces Keytruda in head-and-neck phase II - BioWorld MedTech
Sector Update: Health Care Stocks Decline Late Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
MRUS: BMO Capital Raises Price Target for Merus to $110 | MRUS S - GuruFocus
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled By Stocktwits - Investing.com India
MRUS: BMO Capital Raises Price Target for Merus to $110 | MRUS Stock News - GuruFocus
Merus Shares Surge After Revealing Favorable Interim Cancer Trial Data - marketscreener.com
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled - MSN
Merus Bispecific Impresses In Head And Neck Cancer - insights.citeline.com
Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday - Benzinga
Merus (MRUS) Price Target Increased Following Positive Phase 2 R - GuruFocus
Merus (MRUS) Price Target Raised by BMO Capital as Confidence Grows | MRUS Stock News - GuruFocus
Merus (MRUS) Shares Surge on Promising Cancer Drug Trial Results - GuruFocus
Sector Update: Health Care - marketscreener.com
Merus stock gains on cancer drug data (MRUS:NASDAQ) - Seeking Alpha
MRUS: Analyst Raises Price Target for Merus to $88 | MRUS Stock News - GuruFocus
Merus Says Interim Cancer Trial Data Show 'Robust' Efficacy, Durability; Shares Jump Premarket - marketscreener.com
Merus (MRUS) Gains Extended-Session Momentum On Trial News - Stocks Telegraph
Investors Purchase High Volume of Merus Call Options (NASDAQ:MRUS) - Defense World
Merus (MRUS) Unveils Promising Phase 2 Results in Cancer Treatme - GuruFocus
Merus (MRUS) Unveils Promising Phase 2 Results in Cancer Treatment | MRUS Stock News - GuruFocus
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Mar 21 '25 |
Sale |
48.50 |
4,000 |
193,990 |
11,002 |
| Shuman Harry | VP Controller, PAO |
Jan 01 '25 |
Option Exercise |
0.00 |
5,000 |
0 |
12,002 |
| Lundberg Sven Ante | President, CEO & PEO |
Feb 13 '25 |
Option Exercise |
24.43 |
16,372 |
399,968 |
40,601 |
| Shuman Harry | VP Controller, PAO |
Aug 21 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):